Conditions: Lung Cancer, Non-Small Cell
Keywords: GW786034 pazopanib pemetrexed cisplatin non-small cell lung cancer NSCLC
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 107
Healthy volunteers: no

Brief summary:
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).

Detailed description:

Arms:
arm 1: Investigational treatment (pazopanib and pemetrexed) arm 2: Standard treatment (pemetrexed and cisplatin)

Interventions: intervention 1: pazopanib and pemetrexed intervention 2: pemetrexed and cisplatin
Intervention descriptions: intervention 1: oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily intervention 2: pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks

Protocol document: